Last reviewed · How we verify
Oxybutynin Pill
Oxybutynin Pill is a Small molecule drug developed by Universidad de Valparaiso. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oxybutynin Pill |
|---|---|
| Sponsor | Universidad de Valparaiso |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population (NA)
- Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea (PHASE1, PHASE2)
- Effectiveness of Oral Boldo in Women With Overactive Bladder (PHASE1)
- Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy (NA)
- Effects of Oxytocin and Lorazepam on Fear-related Intra-amygdalar Activity (PHASE1)
- A Study to Compare Oxybutynin to a Placebo in Women and the Effect on Plantar Hyperhidrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybutynin Pill CI brief — competitive landscape report
- Oxybutynin Pill updates RSS · CI watch RSS
- Universidad de Valparaiso portfolio CI
Frequently asked questions about Oxybutynin Pill
What is Oxybutynin Pill?
Who makes Oxybutynin Pill?
What development phase is Oxybutynin Pill in?
Related
- Manufacturer: Universidad de Valparaiso — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing